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Introduction
Cluster headache (CH) is characterised by attacks of
severe unilateral pain in the orbital, supraorbital and/or
temporal areas, lasting from 15 up to 180 min, recurring
up to 8 times daily and accompanied by ipsilateral auto-
nomic symptoms. In the episodic form, headache attacks
usually occur in bouts (cluster periods) lasting from one
week to 1 year, separated by pain-free periods of at least 1
month. In the chronic form these pain-free periods are
absent or last less than a month [1].
Although effective acute treatments are available for
CH attacks, e.g., subcutaneous sumatriptan injections,
most patients need, in addition, preventative therapy.
Several drugs, such as verapamil, methysergide and lithi-
um carbonate, have proven efficacious in the prevention
of CH attacks and shortening of bouts. Oral steroids are
probably the most effective short-term preventative treat-
ment [2], but patients may become steroid-dependent and
develop serious steroid-related adverse effects within a
few months.
Anthony [3] shows that suboccipital injections of a
local anaesthetic alone have neither a beneficial nor a
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Abstract A 44-year-old man
with a past medical history
of episodic cluster headache
presented in our ED with
complaints of multiple daily
cluster headache attacks, with
cervico-occipital spreading of pain
from May to September 2004.
The neurological examination
showed no abnormalities as well
as brain and spine MRI. Great
Occipital Nerve (GON) blockade,
with Lidocaine 2% (5 ml)
and betamethasone (2 mg), were
performed in the right occipital
region (ipsilaterally to cluster
headache), during attack.
GON blockade was effective
immediately for the attack
and the cluster period resolved
after the injection. We suppose
that the action of GON blockade
may involve the trigemino-cervi-
cal complex and we moreover
strongly suggest to use GON
blockade in emergency depart-
ments for cluster headache
with cervico-occipital spreading
as attack abortive therapy,
especially in oxygen and sumatrip-
tan resistant cluster headache
attacks, in patients who com-
plaints sumatriptan side-effects
or have contraindications to use
triptans.
Key words Great occipital nerve
blockade • Cluster headache •
Emergency department
Received: 5 January 2006
Accepted in revised form: 29 March 2006
Published online: 26 April 2006
99
worsening effect on CH attacks and 0.5 ml xylocaine 2%
was also added to the steroid preparation. Ambrosini et al.
[4], in a placebo-controlled study, showed that suboccipi-
tal injection with a mixture of rapid- and long-acting
steroids and xylocaine 2%, which can be used as a single-
shot treatment, is a more effective modality for steroid
therapy of episodic and chronic CH.
We report the case of a 44-year-old man with a history
of episodic CH treated in the emergency department (ED)
with an injection of a mixture of local anaesthetic and
steroid, with complete pain relief lasting one year. We
suggest the use of this therapy on patients with oxygen-
and sumatriptan-resistant CH attacks in the ED and in
patients who complain of sumatriptan side effects or have
contraindications to triptans [5, 6].
Case report
A 44-year-old man with a past medical history of episod-
ic CH presented in our ED with complaints of multiple
daily CH attacks lasting from May to September.
The pain was described as burning, strictly confined to the
right retro-orbital region, spreading to the right occipital
region and usually lasting from 45 min to 3 h. Mean headache
intensity was 10 (Numerical Rating Scale; 0 = no pain, 10 =
the worst pain imaginable). The headaches were associated
with ipsilateral rhinorrhoea, eyelid ptosis, conjunctival con-
gestion, lacrimation, restlessness and a sense of agitation.
Because the headache became daily with multiple attacks
and the pain worsened, he frequently went to the ED (8–10
times) between May and September 2004. Previous therapy
based on methylprednisolone (16 mg bid) and valproic acid
(500 mg/day) was administered by another headache centre
without any success; O2 therapy, indomethacin (50 mg) and
rizatriptan were ineffective for the patient’s attacks, and only
subcutaneous sumatriptan was effective, until the end of
May 2004 when it became uneffective.
In September 2004 he visited our ED and was exam-
ined by a neurologist. The neurological examination
showed no abnormalities, as did brain and spine MRI and
ECG. After informed consent, we performed great occipi-
tal nerve (GON) blockade, with lidocaine 2% (5 ml) and
betamethasone (2 mg), in the right occipital region (ipsi-
laterally to CH), during an attack; the injection of supra-
orbital and maxillary branch of trigeminal nerve was
impossible because the patient was restless because of the
pain. GON blockade was defined as the appearance of
hypo-anaesthesia in the GON area after the procedure.
Clinical response was good: he was pain free in a few
minutes and preventive therapy, started in the previous
Headache Center in August 2004, was not modified. The
patient did not show any side effects after the injection.
At the one-month follow-up visit he reported strong
headache improvement in frequency and intensity from 10
to 1–2 on the NRS and then we gradually stopped preven-
tive therapy. At the one-year follow-up visit (September
2005) he was still pain free.
Discussion
As described by Ambrosini et al. [4], we observed that the
GON blockade was effective by itself in stopping cluster
symptomatology, while our patient was experiencing mul-
tiple cluster attacks per day. We do not know if the cluster
period was spontaneously ending at the time of injection,
but it is improbable because the frequency of the attacks
was increasing. Moreover the temporal relationship
between GON blockade and cluster symptomatology ces-
sation was very strong.
The mechanisms of GON blockade efficacy in CH are
unknown. Busch [7] showed a functional connectivity
between cervical pathway and trigeminal sensory affer-
ents in healthy subjects in a neurophysiological study. He
also demonstrated that it is possible to modulate the
trigeminal nociceptive system by GON blockade.
As a result, we suppose that the action of GON block-
ade in CH with cervico-occipital spreading may involve
the trigemino-cervical complex [8], an overlapping area
between trigeminal and cervical sensory afferent projec-
tions in the central nervous system, producing central
desensitisation of this area and, probably, altering the
trigeminal autonomic reflex pathway [9]. This is probably
the mechanism that would justify the use of GON block-
ade as a transitional preventive therapy and it may explain
the efficacy in our patient as a single-shot therapy.
Rozen [10] suggested that there can be a non-hypo-
thalamic form of CH and that the GON may play a signif-
icant role in cluster pathogenesis in some patients. The
trigeminocervical-hypothalamic connection could secon-
darily activate the hypothalamus.
There is actually no current gold standard of practice
regarding GON injections in the management of primary
headache (PH). Recently, Afridi et al. [11] showed that
tenderness over the GON is strongly predictive of out-
come after GON blockade in PH as CH.
In conclusion we strongly suggest the use of GON
blockade in EDs for CH with cervico-occipital spreading
as attack abortive therapy, especially in oxygen- and
sumatriptan-resistant CH attacks, in patients who com-
plain of sumatriptan side effects or have contraindications
to use of triptans (ischaemic heart disease, obliterating
arteriopathy of the lower extremities, prior acute cere-
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